Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China

Table 3 Baseline features of EGPA patients with and without CNS involvement

Characteristics	With CNS involvement (n = 19)	Without CNS involvement (n = 91)	P value
Demographics
Age (year)	51.7 ± 11.56	43.7 ± 13.78	0.019*
Gender (male/female, number)	10/9	51/40	0.490
Time from allergy to EGPA diagnosis (month)	48 (5, 115)	24 (5, 60)	0.314
Disease duration (month)	11 (4, 39)	5 (2, 14)	0.082
Time from initial symptoms to vasculitis (month)	21 (2, 54)	7 (0, 36)	0.337
Clinical manifestation, n (%)
Weight loss	6 (31.6)	35 (38.5)	0.573
Fever	11 (57.9)	34 (37.4)	0.098
Arthritis	4 (21.1)	13 (14.3)	0.489
Myalgia	6 (31.6)	16 (17.6)	0.207
Allergic rhinitis	6 (31.6)	34 (37.4)	0.634
Severe asthma	13 (68.4)	72 (79.1)	0.368
Cutaneous vasculitis	11 (57.9)	48 (52.7)	0.682
Renal involvement	4 (21.1)	24 (26.4)	0.776
Digestive tract involvement	10 (52.6)	26 (28.6)	0.042*
Peripheral neuropathy	11 (57.9)	40 (44.0)	0.268
Cardiac involvement	5 (26.3)	35 (38.5)	0.317
Ear involvement	4 (21.1)	10 (11.0)	0.258
Sinusitis	11 (57.9)	53 (58.2)	0.978
Laboratory examination
Eos count (10⁹/L)	4.1 (1.5,5.6)	2.6 (1.4,7.6)	0.770
Eos%	37.2 (11.8,50.0)	28.6 (17.1,45.7)	0.483
ESR (mm/1 h)	27 (9,40)	32 (14,54)	0.461
CRP (mg/L)	10.84 (5.34,39.77)	21.70 (4.54,63.85)	0.623
RF (IU/mL)	21.7 (7.0,90.1)	25.0 (10.0,90.4)	0.651
MPO-ANCA, n (%)	3 (15.8)	12 (13.2)	0.721
PR3-ANCA, n (%)	1 (5.3)	1 (1.1)	0.317
Biopsy-proven vasculitis	4 (21.1)	10 (11.0)	0.258
Granuloma, n (%)	1 (5.3)	5 (5.5)	1.000
Clinical score
BVAS	16 (14,22)	14 (10,19)	0.103
FFS ≥ 1, n (%)	16 (84.2)	65 (71.4)	0.250

All the continuous normally distributed data are presented as mean ± standard deviation, and non-normally distributed data as median (first quartile, third quartile)
EGPA, Eosinophilic Granulomatosis with Polyangiitis; CNS, Central Nervous System; Eos, eosinophil; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; MPO, myeloperoxidase; ANCA, anti-neutrophil cytoplasmic antibody; PR3, protease 3; BVAS, Birmingham Vasculitis Activity Score; FFS, five -factor score; *P < 0.05.

ISSN: 1750-1172